ATE207758T1 - Verwendung von igf-1 - Google Patents

Verwendung von igf-1

Info

Publication number
ATE207758T1
ATE207758T1 AT93910528T AT93910528T ATE207758T1 AT E207758 T1 ATE207758 T1 AT E207758T1 AT 93910528 T AT93910528 T AT 93910528T AT 93910528 T AT93910528 T AT 93910528T AT E207758 T1 ATE207758 T1 AT E207758T1
Authority
AT
Austria
Prior art keywords
pct
igf
treatment
medicament
sec
Prior art date
Application number
AT93910528T
Other languages
English (en)
Inventor
David B Dunger
Martin O Savage
Peter H Soenksen
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Application granted granted Critical
Publication of ATE207758T1 publication Critical patent/ATE207758T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT93910528T 1992-05-19 1993-05-14 Verwendung von igf-1 ATE207758T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9201573A SE9201573D0 (sv) 1992-05-19 1992-05-19 Use of igf-1
PCT/SE1993/000425 WO1993023071A1 (en) 1992-05-19 1993-05-14 Use of igf-1

Publications (1)

Publication Number Publication Date
ATE207758T1 true ATE207758T1 (de) 2001-11-15

Family

ID=20386281

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93910528T ATE207758T1 (de) 1992-05-19 1993-05-14 Verwendung von igf-1

Country Status (11)

Country Link
US (1) US5466670A (de)
EP (1) EP0613376B1 (de)
JP (1) JPH06509361A (de)
AT (1) ATE207758T1 (de)
AU (1) AU669894B2 (de)
CA (1) CA2112358A1 (de)
DE (1) DE69331045T2 (de)
NO (1) NO940180L (de)
NZ (1) NZ252359A (de)
SE (1) SE9201573D0 (de)
WO (1) WO1993023071A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681814A (en) * 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
US20020049422A1 (en) * 1994-03-31 2002-04-25 Brewitt Barbara A. Homeopathic preparations
US20060088575A1 (en) * 1994-03-31 2006-04-27 Brewitt Barbara A Homeopathic preparations of purified growth factors and purified growth hormones and associated carriers
SE9402370D0 (sv) * 1994-07-04 1994-07-04 Pharmacia Ab Use of IGF-I
US5741776A (en) * 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
US5565428A (en) * 1995-05-22 1996-10-15 Genentech, Inc. Method of administration of IGF-I
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
US6015786A (en) * 1997-02-25 2000-01-18 Celtrix Pharmaceuticals, Inc. Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
US6514937B1 (en) 1997-02-25 2003-02-04 Celtrix Pharmaceuticals, Inc. Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
US6025368A (en) * 1997-02-25 2000-02-15 Celtrix Pharmaceuticals, Inc. Method for treating the symptoms of chronic stress-related disorders using IGF
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
AU762351B2 (en) 1999-01-06 2003-06-26 Genentech Inc. Insulin-like growth factor (IGF) I mutant variants
AU763039B2 (en) * 1999-04-08 2003-07-10 Genentech Inc. Composition based on oppositely-charged polypeptides
US6040292A (en) * 1999-06-04 2000-03-21 Celtrix Pharmaceuticals, Inc. Methods for treating diabetes
ATE389416T1 (de) 2000-05-16 2008-04-15 Genentech Inc Behandlung von knorpelerkrankungen
RU2165767C1 (ru) * 2000-06-09 2001-04-27 Чернов Юрий Николаевич Антидиабетическое средство
JP2004518647A (ja) 2000-12-15 2004-06-24 ナチュラルエンド テック カンパニー リミテッド インシュリン様成長因子−１の分泌誘導用薬剤学的組成物および食品組成物
CN100439397C (zh) * 2001-02-09 2008-12-03 基因技术股份有限公司 Igf-1的结晶
WO2002072780A2 (en) 2001-03-14 2002-09-19 Genentech, Inc. Igf antagonist peptides
JP2008511838A (ja) 2004-08-30 2008-04-17 テルシカ・インク インシュリン様成長因子欠乏疾患の診断及び治療のための方法及び装置
WO2013050529A2 (en) * 2011-10-06 2013-04-11 European Molecular Biology Laboratory Use of igf-1 in the modulation of treg cell activity and the treatment and prevention of autoimmune disorders or diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207842A (en) * 1983-04-25 1988-02-12 Chiron Corp Production of human insulin-like growth factor (igf) using cdna
US4963665A (en) * 1986-01-07 1990-10-16 Washington University Human preproinsulin-like growth factor I
SE8703625D0 (sv) * 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
US4988675A (en) * 1988-02-05 1991-01-29 Ciba-Geigy Corporation Method for preventing secondary effects
GB8920381D0 (en) * 1989-09-08 1989-10-25 Greater Glasgow Health Board Treatment of insulin-resistant diabetes

Also Published As

Publication number Publication date
NZ252359A (en) 1997-05-26
US5466670A (en) 1995-11-14
AU4098893A (en) 1993-12-13
NO940180D0 (no) 1994-01-18
JPH06509361A (ja) 1994-10-20
EP0613376B1 (de) 2001-10-31
CA2112358A1 (en) 1993-11-25
AU669894B2 (en) 1996-06-27
DE69331045D1 (de) 2001-12-06
DE69331045T2 (de) 2002-03-21
SE9201573D0 (sv) 1992-05-19
NO940180L (no) 1994-01-18
EP0613376A1 (de) 1994-09-07
WO1993023071A1 (en) 1993-11-25

Similar Documents

Publication Publication Date Title
ATE207758T1 (de) Verwendung von igf-1
TR200100079T2 (tr) Glikoza karşı ß-hücre tepkisini arttıran glukagon benzeri peptid-1
ATE82507T1 (de) Medizinische verwendung.
UA27874C2 (uk) Препарат інсуліну людини, спосіб одержання препарату, спосіб лікування цукрового діабету
DE69226835D1 (de) Verfahren und zusammensetzungen zur behandlung von diabetes mellitus, hypoglykämie und anderer krankhafter zustände
DE69218406D1 (de) Verwendung von menschlichem igf-i
TR200001892T2 (tr) Monomer cinsi ensülin analogları ve bunların kullanımı.
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
SI0699686T1 (en) Biologically active fragments of glucagon-like insulinotropic peptide
ATE185548T1 (de) Verwendung von n-arylmethylen ethylendiamintriacetate, n-arylmethylen iminodiacetat oder n,n'-diarylmethylen ethylendiamindiacetat gegen oxidativen stress
ATE169503T1 (de) Rekombinante viren und ihre verwendung bei der gentherapie
ATE138578T1 (de) Behandlung von insulinresistentem diabetes
DE69123361D1 (de) Verwendung von interleukin-4 zur behandlung der festen tumoren
ATE271880T1 (de) Methoden zur behandlung von diabetes
ATE142500T1 (de) Doppelsträngige rns zur korrektur von abnormalitäten von zirkulierenden immunkomplexen und der monozytenfunktion
ZA200107283B (en) Vascular adhesion molecules and modulation of their function.
ATE104855T1 (de) Verwendung von inositoltrisphosphat zur herstellung eines arzneimittels gegen knochenerkrakungen.
DE69717301D1 (de) Verwendung von wachstumshormone
ATE174629T1 (de) Herstellung von proteinen mittels protein 7b2
CA2116535A1 (en) A Method for Treatment of Patients with Chronic Liver Disease
ATE183651T1 (de) Verwendung von wachstumsfaktor igf-ii zur beahandlung von gastrointestinalen störungen
ATE209042T1 (de) Verwendung des wachstumshormons in mitteln zur behandlung der insulinresistenz im herzen
DE69300037D1 (de) Verwendung von Bucillamin zur Herstellung eines Arzneimittels zur Behandlung von Cystinuria.
ATE42201T1 (de) Verwendung von phytosterolglycosiden zur herstellung von arzneimitteln zur behandlung von erhoehtem 5(6)alpha-epoxycholesterolgehalt.
ATE77952T1 (de) Verwendung von 1,4-dihydropyridinderivaten.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties